Ing. Ivana Ježíšková, Ph.D.
Researcher, Department of Internal Medicine, Hematology and Oncology
correspondence Address:
Jihlavská 340/20, 625 00 Brno
phone: | +420 532 23 4628 |
---|---|
e‑mail: |
social and academic networks: |
---|
Total number of publications: 108
2022
-
HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.
Year: 2022, type: Conference abstract
-
Izolovaná infiltrace ledviny suspektními leukemickými buňkami - kazuistika s komplexní diferenciální diagnostikou neobvyklého stavu
Transfuze a hematologie dnes, year: 2022, volume: 28, edition: 1, DOI
-
Komplexní cytogenomická a molekulárně biologická analýza nádorového genomu pacientů s myeloidními malignitami se zaměřením na cílenou analýzu genu MECOM.
Year: 2022, type: Conference abstract
-
Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients.
LEUKEMIA & LYMPHOMA, year: 2022, volume: 63, edition: 13, DOI
-
Somatic mutations are frequently detected in CML patients before treatment-free remission (TFR) attempt with tyrosine kinase inhibitor (TKI) discontinuation but with uncertain predictive valu efor Tfr failure
Year: 2022, type: Conference abstract
-
Somatic mutations in myeloid transcription factors and in activated signaling pathway, but not in epigenetic modifier pathway, predict the risk of tratment failure and progression to advanced phase in chronic myeloid leukemia
Year: 2022, type: Conference abstract
-
Současná role cytogenomiky v diagnostice a prognostické stratifikaci hematologických malignit.
Year: 2022, type: Conference abstract
-
The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy
Year: 2022, type: Conference abstract
-
Využití mutací v genu CEBPA pro sledování minimální reziduální nemoci pomocí sekvenování nové generace u pacientů s akutní myeloidní leukémií
Year: 2022, type: Conference abstract
2021
-
Acute myeloid leukemia regression induced by palbociclib and ponatinib in patient –derived xenograft model.
Year: 2021, type: Conference abstract